RxDoctor Payments Data

Jennifer Avina

Family · Clovis, NMNPI 1790490928

Payments from drug & device makers

$818in general payments, 2019–2025

Across 30 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$180
  • E.r. Squibb & Sons, L.L.C.$140
  • Novo Nordisk$69
  • United Therapeutics Corporation$58
  • Bayer$51
  • Novartis$49
  • plus $272 from 11 others

What the payments were for

  • Food & beverage$818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$818 in reported general payments places this provider in the 75th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$73,052
Medicare patients
125
Services billed
1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$67,406
OzempicSemaglutide34$31,866
JardianceEmpagliflozin19$24,831
TrulicityDulaglutide20$21,523
EliquisApixaban17$19,404
FarxigaDapagliflozin Propanediol15$11,852
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,291
Arnuity ElliptaFluticasone Furoate11$3,086
Albuterol Sulfate HfaAlbuterol Sulfate49$1,455
Atorvastatin Calcium118$970
Levothyroxine Sodium121$970
Gabapentin77$927
Lisinopril112$906
Celecoxib30$876
Omeprazole32$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$15$67,40611 claims
Novo NordiskOzempic$69$31,86634 claims
Boehringer IngelheimJardiance$20$24,83119 claims
GSKArnuity Ellipta$21$3,08611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,080 family providers in New Mexico.

Other family in Clovis

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →